Clinical trial
A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis
NCT03827018 is registered in ClinicalTrials.gov with Kiniksa Pharmaceuticals, Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis
- Lead sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 20, 2018
- Completion date
- November 25, 2020
- Enrollment
- 70 (actual)
- Sites
- 49
Conditions
As the registry lists them; a condition with its own page is linked.